Evidence map›Paper›PMID 42016311›Full record

ArticleiScience2026

Safety evaluation of repeated intra-articular injections of human adipose-derived mesenchymal stem cells in

Zhongjin Chen, Jigang Lei, Xingyi Chen, Haohao Xie, Yuhao Dai, Jingjing Bu, Dong Xu, Liang Xu

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhongjin ChenRegenerative Medicine Business Unit, Cellular Biopharma (Shanghai) Co., Ltd., Shanghai 200233, China.
Jigang LeiRegenerative Medicine Business Unit, Cellular Biopharma (Shanghai) Co., Ltd., Shanghai 200233, China.
Xingyi ChenRegenerative Medicine Business Unit, Cellular Biopharma (Shanghai) Co., Ltd., Shanghai 200233, China.
Haohao XieRegenerative Medicine Business Unit, Cellular Biopharma (Shanghai) Co., Ltd., Shanghai 200233, China.
Yuhao DaiRegenerative Medicine Business Unit, Cellular Biopharma (Shanghai) Co., Ltd., Shanghai 200233, China.
Jingjing BuRegenerative Medicine Business Unit, Cellular Biopharma (Shanghai) Co., Ltd., Shanghai 200233, China.
Dong XuRegenerative Medicine Business Unit, Cellular Biopharma (Shanghai) Co., Ltd., Shanghai 200233, China.
Liang XuRegenerative Medicine Business Unit, Cellular Biopharma (Shanghai) Co., Ltd., Shanghai 200233, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) have demonstrated significant potential in tissue regeneration; however, safety concerns remain a primary barrier to their clinical implementation. To further substantiate and expand upon these safety findings, an exhaustive safety evaluation was performed in non-human primates. No mortalities of

Indexed as

biological sciencesimmunology

Identifiers

PMID42016311
PMCPMC13092469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.